ANTITUMOR EFFECT OF HYDROGEL CISPLATIN ON ZEJDEL ASCITES HEPATOMA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aims and objectives. During regional intraperitoneal chemotherapy cytostatics in prolonged dosage form, in particular, on the basis of various biodegradable hydrogels, such as dextran phosphate are applied. Aim of the study - a comparative evaluation of the antitumor activity ofcisplatin and cisplatin in prolonged dextran phosphate hydrogel form on Zajdel ascites hepatoma. Materials and methods. On 49 white no inbreed rats (n = 7) with implanted intraperitoneal Zajdel ascites hepatoma the antitumor activity of cisplatin in prolonged dextran phosphate hydrogel form with single intraperitoneal injection of the dosage from 3 to 8 mg/kg (≈ maximum tolerated dose, MTD) was evaluated in comparison with officinal cisplatin. The treatment efficacy was assessed by a statistically significant standard criteria: the absence of ascites by 32nd day of the experiment (complete remission) and an increase in life span of rats with ascites (T/C >_125 %, «treatment/control») in comparison with the rats without treatment (tumor growth control, where T/C = 100 %) or treated with officinal cisplatin. Macroscopic, pathomorphological and statistical analysis of the results were used. Results. It has been shown that hydrogel form of cisplatin compared to cisplatin was significantly more effective: complete remission 4/7-6/7 vs 0/7, T/C = 140-188 % vs 91-101 %, the volume of ascites 13,6 ± 6,6 ml vs 50,0 ± 7,9 ml (p = 0,004) because of a better tolerance. Regression analysis confirms that hydrogel form of cisplatin in used dose range significantly improves the rats survival with Zajdel ascites hepatoma, reducing the risk of death from tumor in 7-35 times and the relative risk with the dose of 5,5 mg/kg in 36 times (95 % CI3,86 + 327,60) (p = 0,002-0,005). Conclusions. The data obtained allow considering the hydrogel form of cisplatin as a promising prolonged this drug form of cisplatin by the intraperitoneal therapy and recommending it to preclinical study.

About the authors

M. Yu. Reutovich

Республиканский научно-практический центр онкологии и медицинской радиологии им. Н.Н. Александрова

Author for correspondence.
Email: mihail_revtovich@yahoo.com
Russian Federation

Yu. P. Istomin

Республиканский научно-практический центр онкологии и медицинской радиологии им. Н.Н. Александрова

Russian Federation

O. V. Krasko

Объединенный институт проблем информатики НАН Беларуси

Russian Federation

H. M. Treshalina

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

Russian Federation

P. M. Bychkovsky

Учебно-научно-производственное республиканское унитарное предприятие «Унитехпром БГУ»

Russian Federation

T. L. Yurkshtovich

НИИ физико-химических проблем Белорусского государственного университета

Russian Federation

A. I. Shmak

Республиканский научно-практический центр онкологии и медицинской радиологии им. Н.Н. Александрова

Russian Federation

N. V. Golub

НИИ физико-химических проблем Белорусского государственного университета

Russian Federation

V. A. Alinovskaya

НИИ физико-химических проблем Белорусского государственного университета

Russian Federation

R. I. Kosterova

НИИ физико-химических проблем Белорусского государственного университета

Russian Federation

S. O. Solomevich

НИИ физико-химических проблем Белорусского государственного университета

Russian Federation

Y. I. Rogov

ГУО «Белорусская медицинская академия последипломного образования»

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-53039 от  04.03.2013.